N-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)aniline, 97%, 1g

4-Cyano-4'-pentylbiphenyl, 96.00%, 10g

3-Cyclohexylpiperidine, 95.0%, 500mg

methyl 1-benzyl-3-{[(tert-butoxy)carbonyl]amino}pyrrolidine-3-carboxylate, 95.0%, 5g

6-Bromo-2-(1,3-dioxolan-2-yl)pyridine, 97%, 1g

Seringue microlitre GASTIGHT® série 1700 Point type 2, 100 µl, 1710 RN, 1 pièce

3-hydroxy-6H-benzo[c]chromen-6-one, 95.0%, 5g

N-Carbobenzoxy-D-leucine>97.0%(HPLC)(T)25g

2,3,4,6-Tetraiodobenzoic acid, 97%, 1g

Ethyl 3-methyl-1-phenylpyrazole-5-carboxylate, 95.0%, 5g

N'-((Dimethylamino)methylene)-N,N-dimethylformohydrazonamide, 95.0%, 5g

(S)-3,3,3-Trifluoro-1-phenyl-2-propylamine, 98.0%, 1g

Boc-3,4-difluoro-L-b-homophenylalanine, 98.0%, 250mg